NCT04440267View on ClinicalTrials.gov

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

June 20, 2026

Study Completion Date

December 20, 2027

Conditions
Acute Leukemia of Ambiguous Lineage
Interventions
DRUG

vincristine

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

daunorubicin

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

cyclophosphamide

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

L-Asparaginase

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

prednisone

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

mercaptopurine

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

methotrexate

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

dexamethasone

acute lymphoblastic leukemia (ALL) -based chemotherapy

DRUG

Tyrosine kinase inhibitor

acute lymphoblastic leukemia (ALL) -based chemotherapy

Trial Locations (1)

300020

RECRUITING

HBDH, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER